{"transactions":[{"id":4149414,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171572,"kind":"person","name":"RICKEY DAVID","position":1,"cik":"0001184566","reported_name":"RICKEY DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2017-11-29T22:40:07.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":10800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020."}],"balance_after":10800,"derivative":{"exercise_price":0.3333,"expiration_date":"2020-05-28","underlying":"Common Stock","underlying_shares":10800},"source":{"system":"sec-edgar","filing":"0001209191-17-062903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062903/doc4.xml","form_type":"4"}},{"id":4149413,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171572,"kind":"person","name":"RICKEY DAVID","position":1,"cik":"0001184566","reported_name":"RICKEY DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-11-29T22:40:07.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date."}],"balance_after":6,"derivative":{"exercise_price":0.3333,"exercise_date":"2017-11-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-17-062903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062903/doc4.xml","form_type":"4"}},{"id":4149412,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171572,"kind":"person","name":"RICKEY DAVID","position":1,"cik":"0001184566","reported_name":"RICKEY DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (Right to Buy)","published_at":"2017-11-29T22:40:07.000Z","date":"2017-11-28","kind":"other","acquired":false,"shares":6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."}],"balance_after":0,"derivative":{"exercise_price":1000,"exercise_date":"2017-11-02","expiration_date":"2017-11-21","underlying":"see footnote"},"source":{"system":"sec-edgar","filing":"0001209191-17-062903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062903/doc4.xml","form_type":"4"}},{"id":4479510,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171572,"kind":"person","name":"RICKEY DAVID","position":1,"cik":"0001184566","reported_name":"RICKEY DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)_","published_at":"2017-01-27T22:47:28.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan.  The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant.  The closing sale price on the date of the grant was $1.56."}],"balance_after":25000,"derivative":{"exercise_price":1.56,"exercise_date":"2018-01-26","expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-005971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117005971/doc4.xml","form_type":"4"}}]}